WO2002059318A1 - Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier - Google Patents

Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier Download PDF

Info

Publication number
WO2002059318A1
WO2002059318A1 PCT/KR2001/001657 KR0101657W WO02059318A1 WO 2002059318 A1 WO2002059318 A1 WO 2002059318A1 KR 0101657 W KR0101657 W KR 0101657W WO 02059318 A1 WO02059318 A1 WO 02059318A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
humanized
heavy chain
humanized antibody
substituted
Prior art date
Application number
PCT/KR2001/001657
Other languages
English (en)
Inventor
Hyo-Jeong Hong
Keun-Soo Kim
Original Assignee
Korea Research Institute Of Bioscience And Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0060966A external-priority patent/KR100484054B1/ko
Application filed by Korea Research Institute Of Bioscience And Biotechnology filed Critical Korea Research Institute Of Bioscience And Biotechnology
Priority to EP01974926A priority Critical patent/EP1322761A4/fr
Priority to JP2002559803A priority patent/JP2004517636A/ja
Priority to US10/148,844 priority patent/US20030096403A1/en
Publication of WO2002059318A1 publication Critical patent/WO2002059318A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Definitions

  • the present invention relates to the humanized antibodies to surface antigen S of hepatitis B virus and a preparing method thereof. Particularly, it relates to the humanized antibodies which comprise heavy and light chains having amino acid sequences originated from human antibodies at the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3 of their variable regions, minimizing human anti- mouse antibody (HAMA) response by eliminating peptide sequences from heavy chain of above humanized antibody which bind MHC class II molecules, expression vectors containing each of the heavy and light chain genes of the humanized antibody and transformant which can produce humanized antibody by transfection with heavy and light chain expression vectors and a mass- preparation method of humanized antibody by culturing above transformant.
  • HAMA human anti- mouse antibody
  • Hepatitis B virus invades into human body and causes chronic and acute hepatitis. If the condition grows worse, it can be a pathogen causing cirrhosis and cancer of the liver. It is estimated that up to three hundred millions patients in the .world are infected with HBV (Tiollais & Buendia, Sci . Am . , 264, 48, 1991) .
  • the envelope of HBV is composed of 3 types of proteins. Specifically, it is composed of major protein comprising S antigen, middle protein comprising S antigen and pre-S2 antigen, and large protein comprising S antigen, pre-S2 antigen and pre-Sl antigen (Neurath, A.R. and Kent, S.B.H., Adv.
  • HBV surface antigen proteins can induce antibodies which neutralize HBV.
  • S antigen takes part of about 80% of the total envelop protein and has neutralizing epitope called "Common a" which is commonly present in all of HBV subtypes.
  • HB immune globulin has been used to prevent the HBV infection (Beasley et al., Lancet, 2, 1099, 1983; Todo et al . , Hepatol . , 13, 619, 1991) .
  • HBIG HB immune globulin
  • the currently used HBIG is prepared from human plasma, it has the disadvantages that the specificity against antigen is low and the probability of contamination is relatively high.
  • human blood has to be continuously supplied.
  • mouse monoclonal antibody has the advantages that it has high affinity to antigen and can be mass-produced, whereas, it also has the disadvantages that when administered into human body, it can induce human anti-mouse antibody response (hereinafter, it referred as "HAMA response") in human bodies (Shawler et al . , J. Immunol . , 135, 1530, 1985).
  • HAMA response human anti-mouse antibody response
  • humanized antibody has been developed in which high affinity and specificity of mouse monoclonal antibody is maintaining, while HAMA response is minimizing.
  • Humanized antibody is constructed by grafting the complementarity determining regions (hereinafter, it referred as CDRs") of mouse monoclonal antibody to the framework regions of a human antibody by genetic engineering technique.
  • CDRs complementarity determining regions
  • Such a humanized antibody was shown to be much less immunogenic in humans (Riechmann et al . , Nature, 332, 323, 1988; Nakatani et al . , Protein Engineering, 7, 435, 1994) .
  • the humanized antibody produced by this method also has the disadvantage that the mouse-derived CDRs in the antibody can elicit immune responses when repeatedly administered into human body (Stephens et al . , Immunology, 85, 668- 674, 1995; Sharkey et al . , Cancer Research, 55, 5935s- 5945s, 1995) . Therefore, it is expected that when the amino acid residues of CDRs derived from mouse antibody in humanized antibodies are substituted for human antibody residues, the HAMA response will be decreased.
  • a humanized antibody constructed by grafting the specificity determining residues of mouse monoclonal antibody that are directly involved in antigen binding (hereinafter, it referred as "SDRs") to the framework regions of a human antibody would induce less HAMA response than previously known humanized antibodies.
  • SDRs specificity determining residues of mouse monoclonal antibody that are directly involved in antigen binding
  • Helper T cell is essential in the activation of the early stages in the immune response and MHC (Major Histocompatibility Complex) class II molecule plays an essential role in the selection and activation of the T cells.
  • MHC class II protein binds to peptide having 9 amino acid residues digested from protein antigen and is expressed on the surface of the antigen-presentation cells.
  • the immune responses are initiated when the T cell is activated by complex formation with the T cell receptor (TCR) which recognizes above MHC class II molecule (Germain, R. N. Cell 76, 287-299, 1994) . Therefore, humanized antibody without the peptide sequence that may bind to the MHC molecule would not induce the immune response in humans.
  • TCR T cell receptor
  • humanized antibodies which comprise heavy and light chains having amino acid sequences originated from human antibodies at the HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, CDR3 of their variable regions, minimizing human anti-mouse antibody (HAMA) response by eliminating peptide sequences from heavy chain of above humanized antibody which bind MHC class II molecules, and completed the present invention by showing that it minimizes the probability of immune response in human body and has good antigen binding capacity, making it a excellent candidate for prevention and treatment of the hepatitis B virus infection.
  • HAMA human anti-mouse antibody
  • the object of the present invention is to provide humanized antibody against HBV surface antigen S which minimizes the immunogenicity in the human body while having excellent antigen binding capability and method for preparation thereof in order to prevent and treat hepatitis B virus infection effectively.
  • Fig. 1 shows the result which compares nucleotide and amino acid sequences between the heavy chain variable region of humanized antibody HZII-H67 and the humanized heavy chain variable region mutants of the present invention against surface antigen S of HBV.
  • Fig. 2 shows diagram illustrating the preparing method of humanized heavy chain mutant I34V in which valine is substituted for the 34 th isoleucine of mouse HCDR1.
  • Fig. 3 shows restriction map of expression vector pcDdA-HzSIIIh-I34V which comprises I34V mutant produced by the method of Fig 2.
  • Fig. 4 shows the result of ELISA illustrating antigen binding capacity of the humanized antibody against surface antigen S which has the humanized heavy chain mutant of the present invention, A; HCDR1 mutant, B; HCDR2 mutant,
  • humanized antibody HZII-H67 composed of heavy and light chain of HZII-H67
  • Fig. 5 shows the result of ELISA illustrating antigen binding capacity against surface antigen S of the humanized antibody which comprises more than two humanized heavy chain mutations of the present invention.
  • Fig. 6 shows the result comparing nucleotide and amino acid sequences between the light chain variable region of humanized antibody HZII-H67 and the humanized light chain variable region mutants of the present invention against surface antigen S of HBV.
  • Fig. 7 shows diagram illustrating the preparing method of the humanized heavy chain mutant Q89L in which leucine is substituted for the 89 th glutamine of mouse LCDR1.
  • Fig. 8 shows restriction map of expression vector pcDdA-HzSIIIh-Q89L which comprises Q89L mutant produced by method in Fig 7.
  • Fig. 9 shows the result of ELISA illustrating antigen binding capacity of the humanized antibody against surface antigen S which has the humanized light chain mutant of the present invention, H/K; humanized antibody HZII-H67 composed of heavy and light chain of HZII-H67
  • Fig. 10 shows the result of Western blot analysis illustrating the presence of humanized antibody HzS-III having humanized recombinant heavy chain mutant and light chain mutant of the present invention, A; HzS-III, B; HZII-H67
  • Fig. 11 shows the result of ELISA illustrating antigen binding capacity of the humanized antibody HzS- III against HBV surface antigen S which has the humanized recombinant heavy chain mutant and light chain mutant of the present invention.
  • Fig. 12 shows the result of competitive ELISA illustrating antigen binding affinity of the humanized antibody HzS-III and HzS-IV against HBV surface antigen S which has the humanized recombinant heavy chain mutant and light chain mutant of the present invention.
  • Fig. 10 shows the result of Western blot analysis illustrating the presence of humanized antibody HzS-III having humanized recombinant heavy chain mutant and light chain mutant of the present invention, A; HzS-III, B; HZII-H67
  • FIG. 13 shows the result comparing amino acid sequences between heavy chain variable region of humanized antibody HzS-III and HzS-IV of the present invention and wild type mouse monoclonal antibody H67 and humanized antibody HZII-H67.
  • Fig. 14 shows the result comparing amino acid sequences between light chain variable region of humanized antibody HzS-III of the present invention and wild type mouse monoclonal antibody H67 and humanized antibody HZII-H67.
  • the present invention provides humanized antibody against HBV surface antigen S comprising heavy and light chains in which amino acid residues of human origin is substituted for amino acid residues of CDRs at heavy and light chain variable region of mouse origin; expression vectors comprising each of the heavy and light chain genes of the humanized antibody; and transformant transfected with above expression vector.
  • the present invention provides humanized heavy chain mutant in which amino acid residues at the heavy chain antibody of human origin is substituted for amino acid residues of mouse origin at the HCDRl, HCDR2, HCDR3 region of the corresponding heavy chain variable region of the humanized antibody against HBV surface antigen S, and expression vector comprising the same.
  • humanized antibody of the present invention is constructed by substituting amino acid residues from human antibody origin for amino acid residues of mouse origin that do not influence the antigen binding activity.
  • mice HCDRl region of the humanized antibody HZII-H67 To substitute amino acid of human origin for mouse-originated amino acid residue at HCDRl region of the humanized antibody HZII-H67, Asp-Tyr-Asn-Ile-Gln represented by SEQ. ID. NO: 1, the present inventors compared the amino sequence of mouse HCDRl region with that of the human antibody. In results, it was found that mouse HCDRl had high homology with HCDRl amino acid residue Asp-Tyr-Asn-Val-Asn of human HCDRl antibody sequence represented by SEQ. ID. NO: 2 from the Kabat Database ID Number 35920. So, the present inventors construct HCDRl mutant where 4 th and 5 th amino acid residues showing differences were substituted.
  • mutant I34V or Q35N is constructed in which valine or asparagine was substituted for isoleucine or glutamine at the 34 th or 35 th amino acid residue, which shows differences between mouse and human HCDRl region of the antibodies .
  • Said mutants are constructed by PCR and recombinant PCR using heavy chain expression vector pRc/CMV-HC-HZIIS (KCTC 0489BP) of humanized antibody as a template (see Fig. 1 and Fig. 2) .
  • heavy chain variable region mutant I34V of humanized antibody is constructed by performing recombinant PCR reaction using DNA fragments as templates obtained from HL and PI primer pairs represented by SEQ. ID. No: 3 and SEQ. ID. No: 4 and P2 and HC primer pairs represented by SEQ. ID. No: 5 and SEQ. ID. No: 6, respectively, and HL and HC as primer pairs.
  • recombinant expression vector is constructed by cloning above I34V mutant into expression vector in which cDNA for humanized heavy chain antibody is cloned and was referred as pcDdA-HzSIIIh-l34V (see Fig. 3) .
  • pcDdA-HzSIIIh-l34V cDNA for humanized heavy chain antibody
  • Q35N mutant is constructed by performing PCR and recombinant PCR by the same method using primer pairs represented by SEQ. ID. No: 3, SEQ. ID. No: 7, SEQ. ID. No: 8 and SEQ. ID. No. 6, in which, among amino acid residues showing differences between HCDRl sequences at the mouse and human antibodies, asparagine from human heavy chain is substituted for glutamine at the 5 th amino acid residue.
  • recombinant expression vector pcDdA-HzSIIIh-Q35N is generated by cloning Q35N into expression vector.
  • human-originated HCDR2 amino acid sequence is substituted for all of the mouse- originated HCDR2 amino acid sequence, except amino acid residues directly involved in the antigen binding.
  • amino acid sequences at the HCDR2 region of mouse and human origin are compared. After finding the homology between mouse HCDR2 and HCDR2 region at the heavy chain of human antibody DP-15, HCDR2 mutant is constructed using the same method as above by substituting amino acid residues which are not directly involved in the binding to the antigen.
  • I51M mutant in which methionine is substituted for isoleucine at the 51 st amino acid residue of the HCDR2 (using primer pairs represented by SEQ. ID. No: 9 and SEQ. ID. No: 10) and recombinant expression vector pcDdA-HzSIIIh-I5lM comprising the same, and T54S mutant in which serine is substituted for threonine at the 54 th amino acid residue (using primer pairs represented by SEQ. ID. No: 11 and SEQ. ID.
  • humanized antibody of the present invention wherein amino acid residues from human antibody are substituted for amino acid residues at the mouse HCDR3 region of humanized antibody HZII- H67, it is preferred that human-originated HCDR3 amino acid sequence is substituted for all of the mouse- originated HCDR3 amino acid sequence, except amino acid residues directly involved in the antigen binding.
  • alanine scanning mutagenesis of the mouse HCDR3 was carried out to identify which amino acid residue is directly involved in the antigen binding.
  • N95A mutant in which alanine is substituted for aspargine at the 95 th amino acid residue of the HCDR3 (using primer pairs represented by SEQ. ID. No: 15 and SEQ. ID. No: 16) and recombinant expression vector pcDdA-HzSIIIh-N95A comprising the same
  • Y96A mutant in which alanine is substituted for tyrosine at the 96 th amino acid residue (using primer pairs represented by SEQ. ID. No: 17 and SEQ. ID.
  • humanized antibody of the present invention is more humanized than that of the previous art by substituting human-originated amino acids for the mouse-originated amino acids, which are not directly involved in the antigen binding and thus are not expected to affect antigen binding affinity, at the CDR region of the humanized antibody.
  • SDR-grafting method is employed in the present invention to make humanized antibody having less HAMA response and improved therapeutic effect, wherein SDR regions directly involved in the binding to the HBV surface antigen S are substituted into human antibody. That is different from previous methods in which all of the amino acids in the CDR regions of the mouse antibody showing homology are substituted into the human antibody.
  • the present inventors transfected animal cells with each of the recombinant expression vectors comprising each of the mutant genes at the heavy chain. After measuring the concentrations of antibody that is expressed from above transfectant by sandwich ELISA, antigen binding capacity of the humanized antibody comprising humanized heavy chain mutant against surface antigen S was measured using indirect ELISA. In results, among the HCDRl mutants, the binding ability of I34V against the HBV surface antigen S was almost the same as that of the heavy chain of the wild type humanized antibody HZS-H67.
  • the amino acid sequence of human antibody HCDR3 in the data base was compared with that of the mouse HCDR3 in the humanized antibody HZII-H67 in order to substitute the above glutamate residue for that of human antibody.
  • serine and glycine of the 100 th and 101 st amino acid residue of HCDR3 were consensus amino acid residue.
  • the present inventors constructed mutants wherein serine or glycine was substitute for glutamate or alanine of the 100 th and 101 st amino acid, respectively, and measured the antigen binding capacity of them.
  • ElOOS mutant in which serine is substituted, for glutamate at the 100 th amino acid residue (using primer pairs represented by SEQ. ID. No: 29 and SEQ. ID. No: 30) and recombinant expression vector pcDdA-HzSIIIh- E100S comprising the same, and A101G mutant in which glycine is substituted for alanine at the 101 st amino acid residue (using primer pairs represented by SEQ. ID. No: 31 and SEQ. ID. No: 32) and recombinant expression vector pcDdA-HzSIIIh-AlOlG comprising the same are constructed. After measuring antigen binding ability of humanized antibody having humanized heavy chain mutant against surface antigen S, it was found that antigen binding capacity of ElOOS was similar to that of the wild type, whereas A101G showed slightly decreased antigen binding capacity.
  • PCR and subcloning were performed using pcDdA-HzSIIIh-T54S as template by the same method described before, and the expression vector constructed from this was referred to as pcDdA- HzSIIIh-T54S+I34V.
  • PCR and subcloning were performed using pcDdA-HzSIIIh-l34V as template by the same method described before, and the expression vector obtained from this was referred to as pcDdA- HzSIIIh-T54S+I34V+E100S .
  • the present inventors transfected animal cells with the recombinant expression vectors comprising the same and measured antigen binding capacity of the humanized antibody against surface antigen ⁇ using indirect ELISA.
  • the expression vector pcDdA-HzSIIIh which expresses heavy chain recombinant mutant showing antigen binding capacity against HBV surface antigen S has been deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Sep. 22, 2000 (Accession No: KCTC 10083BP) .
  • the present invention provides humanized light chain mutant produced by SDR-grafting method in which amino acid residues at the light chain antibody of human origin is substituted for amino acid residues at the LCDRl, LCDR2, LCDR3 region of the corresponding light chain variable region of the humanized antibody against HBV surface antigen S, and expression vector comprising the same.
  • Humanized antibody of the present invention is constructed by substituting human-originated light chain amino acid residues for amino acid residues at the LCDRl, LCDR2 and LCDR3 of the light chain variable region of the humanized antibody HZII-H67.
  • the LCDRl and LCDR2 of humanized antibody HZII-H67 already has amino acid residues originated from human antibody (in case of LCDRl, D27cS, S31N, M33I; in case of LCDR2, Q54K, S56T) . So, the present inventors tried to change the amino acid residues in the LCDR3.
  • the present inventors compared the amino acid sequence of humanized light chain with the LCDR3 amino acid sequence of light chain of humanized BI antibody showing high homology with it (see Fig. 6) . From this, the present inventors assumed that the 89 th and 91 st amino acid residue glutamine and threonine of the mouse-originated LCDR3 are not directly involved in the antigen binding. So, we substituted them with leucine and serine of the amino acid residues in the human antibody.
  • the present inventors transfected animal cells with the recombinant expression vectors comprising each of the mutant and measured antigen binding capacity of the humanized antibody using indirect ELISA.
  • humanized light chain containing T91S mutant wherein serine was substituted for threonine at the 91 st amino acid residue showed the same extent of binding ability against the surface antigen S as that of the heavy chain of the wild type humanized antibody HZS-H67
  • expression vector pCMV-dhfr-HzSIIIk-T91S of the present invention expressing T91S mutant was referred as pCMV-dhfr-HzSIIIk.
  • the expression vector pcDdA-HzSIIIk which expresses mutant T91S showing antigen binding capacity against HBV surface antigen S has been deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Sep.
  • the present invention also provides humanized antibody comprising heavy and light chain gene in which amino acid residues of human origin is substituted for amino acid residues of mouse origin at the heavy and light chain variable regions of the mouse monoclonal antibody H67 against HBV surface antigen S.
  • humanized antibody comprising recombinant heavy and light chain mutants
  • the present inventors transfected animal cells with humanized heavy chain expression vector pCDdA-HzSIIIh and humanized light chain expression vector pCMV-dhfr-HzSIIIk.
  • humanized antibody HzS-III having humanized heavy and light chain recombinant mutations at the same time was expressed by incubating selected transformant for 48 hours.
  • antigen binding capacity was measured using indirect ELISA.
  • the humanized antibody HzS-III showed binding ability against surface antigen S to almost the same extent as that of the wild type humanized antibody HZS-H67 (H/K) (see Fig. 11).
  • the present inventors measured antigen binding affinity of humanized antibody HzS-III using competitive ELISA (competitive ELISA, Ryu et al . , J. Med. Virol . , 52, 226, 1997). In results, it was found that, in spite of the substitution of human- originated amino acid residues for the mouse- originated amino acid residues, antigen binding affinity of humanized antibody HzS-III of the present invention was almost same as that of the wild type humanized antibody HZII-H67 (see Fig. 12) .
  • the expression vector has been deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Sep. 26, 2001 (Accession No: KCTC 10080BP) .
  • humanized heavy chain expression vector pcDdA-HzSIVh and humanized light chain expression vector pCMV-dhfr-HzSIIIk were transfecting humanized heavy chain expression vector pcDdA-HzSIVh and humanized light chain expression vector pCMV-dhfr-HzSIIIk into animal cell line.
  • humanized antibody HzS-IV was expressed from above transformant by incubating it for 48 hours. Measuring antigen binding affinity of humanized antibody HzS-IV present in the resulting supernatant, it was found that humanized antibody HzS-IV of the present invention showed almost the same affinity as that of humanized antibody HZS-III (see Fig. 12) .
  • humanized antibody HzS-III and HzS-IV showing excellent binding capacity and antigen binding affinity against HBV surface antigen S was compared with the amino acid sequence of wild type mouse monoclonal antibody H67 and humanized antibody HZII-H67.
  • humanized antibody HzS-III and HzS-IV of the present invention contained less amino acid of mouse origin than that of the mouse monoclonal antibody H67 and humanized antibody HZII-H67, because some of the amino acid residues from mouse origin at HCDRl, HCDR2, HCDR3 of the heavy chain or LCDRl, LCDR2, LCDR3 of the light chain were changed with that of the human origin.
  • humanized antibody HzS-III and HzS-IV of the present invention can be good candidates for the prevention of hepatitis B virus infection since they show excellent HBV binding activity and induce lower HAMA response than the humanized antibodies of the previous arts.
  • EXAMPLE 1 Mutation of the gene coding humanized heavy chain antibody 1-1 : Construction of HCDRl mutant
  • DNA fragment of 181 bp in size was amplified from PCR reaction using HL and PI primers represented by SEQ. ID. No: 3 and SEQ. ID. No: 4, and DNA fragment of 284 bp in size was amplified from PCR reaction using P2 and HC primers represented by SEQ. ID. No: 5 and SEQ. ID. No: 6.
  • P2 and HC primers represented by SEQ. ID. No: 5 and SEQ. ID. No: 6.
  • variable region of I34V mutant After digestion of both ends of variable region of I34V mutant using restriction enzyme EcoRI and ApaI, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apal restriction enzyme site of pcDdA-HC expression vector (expression vector in which heavy chain gene of humanized antibody against preSl antigen of HBV (Korea patent application number 1998-49663) was cloned at the EcoRI-Notl site of pcDNA2 from Invitrogen company) and referred it as pcDdA-HzSIIIh-I34V (Fig. 3). After nucleotide sequence analysis of heavy chain variable region I34V mutant of humanized antibody, the present inventors found that heavy chain variable region I34V mutant of humanized antibody was rightly inserted in the above recombinant expression vector.
  • mutant Q35N where asparagine was substituted for glutamine at the 35 th amino acid residue, which shows differences between mouse and human HCDRl antibodies and is not considered to bind directly at the epitope region of the antigen
  • PCR was performed under the same conditions as Example ⁇ 1-1-1>.
  • DNA fragment of 187 bp in size was amplified using HL and P3 primers represented by SEQ. ID. No: 3 and SEQ. ID. No: 1
  • DNA fragment of 278 bp in size was amplified using HC and P4 primers represented by SEQ. ID. No: 6 and SEQ. ID. No: 8.
  • Heavy chain variable region mutant of humanized antibody of 448 bp in size, Q35N was obtained by ligating these two fragments. After digestion of both ends of variable region of Q35N mutant using restriction enzyme EcoRI and ApaI, the present inventors constructed recombinant expression vector by cloning above fragment into the i_7coJ.I-ApaI restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh-Q35N. After nucleotide sequence analysis of heavy chain variable region Q35N mutant of humanized antibody, the present inventors found that heavy chain variable region Q35N mutant of humanized antibody was rightly inserted in the above recombinant expression vector.
  • mice CDR2 had high homology with amino acid sequence of HCDR2 region at the fragment of germline human antibody' s heavy chain, DP-15, represented by SEQ. ID. NO: 40. So, the present inventors constructed HCDR2 mutant by substituting amino acid residues which seem not to be involved directly in the binding of antigen.
  • HCDR2 mutant Construction of mutant where methionine was substituted for isoleucine at the 51 th amino acid residue
  • PCR was performed using P5 and P6 primers represented by SEQ. ID. No: 9 and SEQ. ID. No: 10 instead of PI and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 236 bp in size was amplified using HL and P5 primers, and DNA fragment of 230 bp in size was amplified using HC and P4 primers .
  • heavy chain variable region mutant I51M of humanized antibody of 448 bp in size was obtained.
  • the present inventors constructed recombinant expression vector by cloning above fragment into the -5co.RI-ApaI restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- I51M.
  • the present inventors found that I51M mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • the present inventors After digestion of both ends of variable region of the above mutant T54S using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh-T54S. After nucleotide sequence analysis of T54S mutant of heavy chain variable region of humanized antibody, the present inventors found that T54S mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • PCR was performed using P9 and P10 primers represented by SEQ. ID. No: 13 and SEQ. ID. No: 14 instead of PI and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 278 bp in size was amplified using HL and P9 primers, and DNA fragment of 185 bp in size was amplified using HC and P10 primers.
  • heavy chain variable region mutant S65G of humanized antibody of 448 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant S65G using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the --.cojRI-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh-S65G. After nucleotide sequence analysis of S65G mutant of heavy chain variable region of humanized antibody, the present inventors found that S65G mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • HCDR3 mutant To substitute humanized amino acid for mouse originated amino acid residue at HCDR3 of the humanized antibody HZII-H67 represented by SEQ. ID. NO: 41, the present inventors compared the amino sequences of mouse HCDR3 antibody with that of the human origin. After that, the present inventors constructed HCDR3 mutant by substituting amino acid residues in the mouse HCDR3 sequences which were seemed not to be involved directly in the binding to the antigen.
  • PCR was performed using Pll and P12 primers represented by SEQ. ID. No: 15 and SEQ. ID. No: 16 instead of Pi and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 381 bp in size was amplified using HL and Pll primers, and DNA fragment of 88 bp in size was amplified using HC and P12 primers .
  • heavy chain variable region mutant N95A of humanized antibody of 448 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant N95A using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the --7coJ.I-ApaI restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- N95A. After nucleotide sequence analysis of N95A mutant of heavy chain variable region of humanized antibody, the present inventors found that N95A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • the present inventors After digestion of both ends of variable region of the above mutant Y96A using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the --.co.RI-ApaI restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- Y96A. After nucleotide sequence analysis of Y96A mutant of heavy chain variable region of humanized antibody, the present inventors found that Y96A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • PCR was performed using P15 and P16 primers represented by SEQ. ID. No: 19 and SEQ. ID. No: 20 instead of PI and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 383 bp in size was amplified using HL and P15 primers
  • DNA fragment of 82 bp in size was amplified using HC and P14 primers.
  • heavy chain variable region mutant G97A of humanized antibody of 448 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant G97A using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- G97A. After nucleotide sequence analysis of Y96A mutant of heavy chain variable region of humanized antibody, the present inventors found that G97A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • PCR was performed using P17 and P18 primers represented by SEQ. ID. No: 21 and SEQ. ID. No: 22 instead of PI and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 386 bp in size was amplified using HL and P17 primers
  • DNA fragment of 78 bp in size was amplified using HC and P18 primers.
  • heavy chain variable region mutant Y98A of humanized antibody of 448 bp in size was obtained.
  • variable region of the above mutant Y98A After digestion of both ends of variable region of the above mutant Y98A using restriction enzyme i-.co.RI and ApaI, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- Y98A. After nucleotide sequence analysis of Y98A mutant of heavy chain variable region of humanized antibody, the present inventors found that Y98A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • PCR was performed using P19 and P20 primers represented by SEQ. ID. No: 23 and SEQ. ID. No: 24 instead of PI and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 390 bp in size was amplified using HL and P19 primers
  • DNA fragment of 73 bp in size was amplified using HC and P20 primers .
  • heavy chain variable region mutant D99A of humanized antibody of 448 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant D99A using restriction enzyme - ⁇ co.RI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the --.co-I-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- D99A. After nucleotide sequence analysis of Y98A mutant of heavy chain variable region of humanized antibody, the present inventors found that D99A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • PCR was performed using P21 and P22 primers represented by SEQ. ID. No: 25 and SEQ. ID. No: 26 instead of PI and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 390 bp in size was amplified using HL and P21 primers, and DNA fragment of 73 bp in size was amplified using HC and P22 primers.
  • heavy chain variable region mutant E100A of humanized antibody of 448 bp in size was obtained.
  • variable region of the above mutant E100A After digestion of both ends of variable region of the above mutant E100A using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- E100A. After nucleotide sequence analysis of Y98A mutant of heavy chain variable region of humanized antibody, the present inventors found that E100A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • the present inventors After digestion of both ends of variable region of the above mutant SlOOaA using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the _-.co.RI-ApaI restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- SlOOaA. After nucleotide sequence analysis of Y98A mutant of heavy chain variable region of humanized antibody, the present inventors found that SlOOaA mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • EXAMPLE 2 The expression of humanized antibody having humanized heavy chain mutant
  • the expression vectors of the present invention were transfected into animal cell lines.
  • the C0S7 cells were sub-cultured in DMEM medium (GIBCO) supplied with 10% fetal bovine serum at 37 ° C, 5% CO- incubator.
  • the cells were seeded to the 100 mm culturing dish at 1 x IO 6 cells/i ⁇ C concentrations and cultured overnight at 37 ° C . After that, they were washed 3 times with OPTI-MEM I (GIBCO) .
  • each recombinant expression vector comprising humanized heavy chain mutant of I34V, Q35N, I51M, T54S, S65G, N95A, Y96A, G97A, Y98A, D99A, E100A or SlOOaA constructed in Example 1 and light chain expression vector pKC-dhfr-HZIIS (KCTC 0490BP) of humanized antibody HZII were diluted with 800 ⁇ l of OPTI-MEM I, and 50 ⁇ l of Lipofectamine (GIBCO) was also diluted with 800 ⁇ l of OPTI-MEM I.
  • KCTC 0490BP light chain expression vector pKC-dhfr-HZIIS
  • DNA- lipofectamine complex was produced by mixing the diluted solutions in 15 ml tube and was incubated at room temperature for at least 15 minutes. 6.4 ml of OPTI-MEM I was added to each of the DNA-Lipofectamine complex and it was transfected by uniformly mixing them with washed COS7 cells. Transfection was performed by incubating cells treated with DNA- Lipofectamine complex at 37 ° C , 5% C0 2 incubator for 48 hours. Then, supernatant was collected and antibody concentration was measured using sandwich ELISA method. In order to perform sandwich ELISA, anti-human IgG (Sigma Co.) was used as capture antibody and anti- human antibody (Fc specific) combined with horseradish peroxidase (Sigma Co.) was used as secondary antibody.
  • sandwich ELISA anti-human IgG (Sigma Co.) was used as capture antibody and anti- human antibody (Fc specific) combined with horseradish peroxidase (Sigma Co.) was used as secondary antibody.
  • EXAMPLE 3 Measurement of antigen binding capacity against the surface antigen S of humanized antibody having humanized heavy chain mutant
  • the surface antigen S (Greencross Co.) of HBV was coated by adding it to each well of the micro plate in the amount of 250 ng.
  • Example 2 was added to the plate so that the concentration of each antibody based on the antibody concentration measured in Example 2 might be 0, 0.2, 0.4, 0.8, 1.8, 3.5 and 7 ng, respectively.
  • the optical density was measured at 492 nm after indirect ELISA which was performed by adding anti-human antibody as a secondary antibody combined with horseradish peroxidase to above well plate.
  • HZII-H67 pRc/CMV-HC- HZIIS KCTC 0489BP
  • pKC-dhfr-HZIIS as heavy and light chain expression vector, respectively. The result was shown in Fig. 4.
  • the present inventors confirmed in the above Example 3 that 100 th amino acid residue glutamate (ElOO) from mouse HCDR3 sequence was not important in the binding with HBV surface antigen S. So, we compared it with the amino acid sequence of human antibody CDR3 in the data base in order to substitute the above amino acid residue for that of another human antibody.
  • PCR was performed using P25 and P26 primers represented by SEQ. ID. No: 29 and SEQ. ID. No: 30 instead of Pi and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 390 bp in size was amplified using HL and P25 primers, and DNA fragment of 73 bp in size was amplified using HC and P26 primers.
  • heavy chain variable region mutant E100A of humanized antibody of 448 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant E100A using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- E100A. After nucleotide sequence analysis of E100A mutant of heavy chain variable region of humanized antibody, the present inventors found that E100A mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • PCR was performed using P27 and P28 primers represented by SEQ. ID. No: 31 and SEQ. ID. No: 32 instead of Pi and P2 primers by the same method as in Example ⁇ 1-1-1>.
  • DNA fragment of 396 bp in size was amplified using HL and P27 primers
  • DNA fragment of 68 bp in size was amplified using HC and P28 primers .
  • heavy chain variable region mutant A101G of humanized antibody of 448 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant A101G using restriction enzyme EcoRI and Apal, the present inventors constructed recombinant expression vector by cloning above fragment into the EcoRI-Apa restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIIIh- A101G. After nucleotide sequence analysis of A101G mutant of heavy chain variable region of humanized antibody, the present inventors found that A101G mutant of heavy chain variable region of humanized antibody was rightly inserted in the above recombinant expression vector.
  • Example 3 and ⁇ 4-3> From the results of Example 3 and ⁇ 4-3>, the present inventors confirmed that among the humanized heavy chain mutant, antigen binding capacity of I34V, T54S, S65G and ElOOS was similar to that of the wild type. So, we constructed recombinant mutant comprising all of the 4 mutations at the same time.
  • EXAMPLE 5 Recombinant mutant of humanized heavy chain gene 5-1 : Construction of recombinant mutant T54S+I34V
  • PCR and subcloning were performed using the heavy chain gene expression vector pcDdA-HzSIIIh-l34V of the above Example ⁇ 5-l> as templates by the same method as in Example ⁇ 1-1-1>.
  • the expression vector obtained from this was referred to as pcDdA-HzSIIIh-T54S+I34V+E100S.
  • EXAMPLE 6 Measurement of the antigen binding capacity of humanized antibody having humanized heavy chain recombinant mutant
  • Example 2 After coating the surface antigen S of HBV (Greencross Co.) by adding it to each well of the microplate in the amount of 250 ng, C0S7 cell was transfected with each of the recombinant expression vectors or pKC-dhfr-HZIIS vector constructed in the above Example ⁇ 4-l> to ⁇ 4-3> by the same method as in Example 2. Each medium containing above transfected cells was added to the plate so that the concentration of each antibody might be 0.625, 1.25, 2.5, 5, 10 and 20 ng, respectively. Then, the optical density was measured using the same method of Example 2.
  • the expression vector pcDdA-HzSIIIh which expresses heavy chain recombinant mutant showing antigen binding capacity against HBV surface antigen S has been deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Sep. 22, 2000 (Accession No: KCTC 10083BP) .
  • the LCDRl and LCDR2 of humanized antibody HZII-H67 already has amino acid residues originated from human antibody. So, the present inventors tried to change the amino acid residues in the LCDR3.
  • the present inventors compared the amino acid sequence of humanized light chain with the LCDR3 amino acid sequence of light chain of humanized BI antibody showing high homology with it. From this, the present inventors assumed that the 89 th and 91 st amino acid residue glutamine and threonine of the mouse- originated LCDR3 are not directly involved in the antigen binding. So, we substituted them with leucine and serine of the corresponding light chain residues at the human BI antibody.
  • PCR and recombinant PCR were performed using primers represented by SEQ. ID. No: 33 and SEQ. ID. No: 36 using light chain expression vector pKC-dhkr-HzIIS of the humanized antibody HZII-H67 as templates (Fig. 6 and Fig. 7) .
  • DNA fragment of 336 bp in size was amplified from the PCR using LL and P29 primers represented by SEQ. ID. No: 33 and SEQ. ID. No: 36, and DNA fragment of 273 bp in size was amplified from the PCR using P30 and LC primers represented by SEQ. ID. No: 35 and SEQ. ID. No: 36.
  • the present inventors After obtaining humanized light chain mutant fragment by digesting above pBlue-HzSIIIk-Q89L DNA using restriction enzyme HindiII and Apal, the present inventors constructed recombinant expression vector by re-cloning above fragment into the HindiII-Apal site of pCMV-dhfr expression vector (Fig. 7), and referred it as pCMV- dhfr-HzSIIIk-Q89L (Fig. 8) .
  • PCR was performed using primers represented by SEQ. ID. No: 33, SEQ. ID. No: 36, SEQ. ID. No: 37 and SEQ. ID. No: 38 at the same reaction conditions as in Example ⁇ 7-l>.
  • DNA fragment of 369 bp in size was amplified using LL and P31 primers, and DNA fragment of 391 bp in size was amplified using P32 and LC primers.
  • P32 and LC primers By performing recombinant PCR reaction using above two DNA fragments as templates and LL and LC primer pairs and ligating these two fragments, light chain variable region mutant T91S of humanized antibody of 743 bp in size was obtained.
  • the present inventors After digestion of both ends of variable region of the above mutant T91S using restriction enzyme HindiII and Sail, the present inventors constructed recombinant plasmid by cloning at pBluescript KS+. After nucleotide sequence analysis of T91S mutant of light chain variable region of humanized antibody, the present inventors found that T91S was rightly inserted in the above recombinant expression vector.
  • the present inventors After obtaining humanized light chain mutant fragment by digesting above pBlue-HzSIIIk-T89S DNA using restriction enzyme HindiII and Apal, the present inventors constructed recombinant expression vector pCMV-dhfr-HzSIIIk-T91S by re-cloning above fragment into the HindiII-Apal site of pCMV-dhfr expression vector, and referred it as pCMV-dhfr-HzSIIIk-T91S.
  • EXAMPLE 8 Measurement of the binding ability against HBV surface antigen S of humanized antibody having humanized light chain mutant
  • the expression vector pcDdA-HzSIIIk which expresses mutant T91S showing antigen binding capacity against HBV surface antigen S has been deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Sep. 22, 2000 (Accession No: KCTC 10084BP) .
  • KRIBB Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology
  • KCTC 10084BP accesion No: KCTC 10084BP
  • EXAMPLE 9 Measurement of the antigen binding capacity of humanized antibody (HzS-III) having humanized heavy and light chain recombinant mutant
  • humanized antibody HzS-III having humanized heavy and light chain recombinant mutations at the same time was expressed by incubating selected transformant for 48 hours.
  • Western blot analysis was performed using secondary antibody wherein horseradish peroxidase (Sigma Co.) was combined at the anti-human antibody (Fc specific) .
  • humanized heavy chain of about 55 kDa in size and humanized light chain of about 27 kDa in size were detected. So, the present inventors found that humanized antibody of the present invention was rightly expressed and secreted from the transformant.
  • humanized antibody HzS-III having humanized heavy and light chain recombinant mutations at the same time showed binding ability against surface antigen S to almost the same extent as that of the wild type humanized antibody HZS-H67 (H/K) .
  • antigen binding affinity of humanized antibody HzS-III of the present invention was about 4 x IO 9 M _1 , which did not show large differences with that of the control HZII-H67 (3.2 x 10 9 M "1 ) .
  • EXAMPLE 11 Construction of humanized antibody HzS-IV wherein peptide sequence which binds to MHC class II molecule is removed from humanized antibody HzS-III
  • the present inventors investigated whether peptide sequence which binds to MHC class II molecule was present at the above humanized antibody HzS-III using Sturniolo' s method (TEPITOPE) (Sturniolo et al . , Nature Biotechnology, 17, 555-561, 1999).
  • TEPITOPE Sturniolo' s method
  • the present inventors searched sequences from the human germline DP-25 protein showing high homology with that of above humanized antibody, and excluded it from consideration.
  • the first peptide had amino acid sequence represented by SEQ. ID. No: 44 and was found to be bound with 22 MHC class II out of the 51 MHC class II molecules.
  • the second peptide had amino acid sequence represented by SEQ. ID. No: 45 and was found to be bound with 14 MHC class II molecules (Table 1) .
  • the present inventors substituted threonine for serine at the P9 position of amino acid sequence represented by SEQ. ID. No: 44, and aspartate for threonine at the P6 position of amino acid sequence represented by SEQ. ID. No: 45.
  • the number of MHC class II molecules which could bind to the peptides was decreased to 11 (55%) in case of SEQ. ID. No: 44.
  • SEQ. ID. No: 45 only 1 molecule among 51 MHC class II molecules could bind to peptide.
  • S44T/T68D mutant having mutations of S44T and T68D was constructed, in which threonine was substituted for serine at the 44 th position (using primer pairs represented by SEQ. ID. No: 46 and 47) and aspartate for threonine at the 68 th position (using primer pairs represented by SEQ. ID. No: 48 and 49) , respectively.
  • the present inventors constructed recombinant expression vector by cloning above fragment into the --.co-I-Apal restriction enzyme site of pcDdA-HC expression vector and referred it as pcDdA-HzSIVh.
  • the expression vector has been deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) on Sep. 26, 2001 (Accession No: KCTC 10080BP) .
  • humanized antibody HzS-IV After transfecting humanized heavy chain expression vector pcDdA-HzSIVh and humanized light chain expression vector pCMV-dhfr-HzSIIIk into animal cell line, humanized antibody HzS-IV was expressed from above transformant by incubating it for 48 hours. Measuring antigen binding affinity of humanized antibody HzS-IV present in the resulting supernatant, it was found that humanized antibody HzS-IV of the present invention showed almost the same extent of binding affinity as that of humanized antibody HZS-III (see Fig. 12) .
  • EXAMPLE 12 Comparison between the amino acid sequences of humanized antibody HzS-III and HzS-IV
  • Amino acid sequences of the heavy/light chain variable region of humanized antibody HzS-III and HzS- IV was compared with the amino acid sequence of wild type mouse monoclonal antibody H67 and humanized antibody HZII-H67.
  • humanized antibody HzS-III and HzS-IV of the present invention might cause lower HAMA response, because amino acid sequences of the heavy/light chain variable region of humanized antibody HzS-III and HzS-IV contained less amino acid residues of mouse origin at HCDRl, HCDR2, HCDR3 of the heavy chain or LCDRl, LCDR2, LCDR3 of the light chain than that of the mouse monoclonal antibody H67 and humanized antibody HZII-H67, and HzS-IV had fewer amino acid sequences than HzS-III which could bind to MHC class molecules. Therefore, humanized antibody HzS-III and HzS-IV of the present invention can be good candidates for the prevention of hepatitis B virus since they induce lower HAMA response than the humanized antibodies of the previous arts.
  • humanized antibody of the present invention against HBV surface antigen S is more humanized than that of the previous arts by substituting human-originated amino acid residues for mouse-originated amino acid residues at HCDRl, HCDR2,
  • humanized antibody of the present invention can be useful for the prevention of hepatitis B virus infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps humanisés dirigés contre l'antigène S de surface du virus de l'hépatite B et un procédé de préparation de ces derniers. L'invention concerne notamment des anticorps humanisés qui comprennent des chaînes lourdes et légères dotées de séquences d'acides aminés provenant d'anticorps humains aux sites HCDR1, HCDR2, HCDR3 et LCDR1, LCDR2, LCDR3 de leurs régions variables, des vecteurs d'expression contenant chacun des gènes de chaînes lourdes et légères de l'anticorps et du transformant humanisés qui peuvent produire un anticorps humanisé par transfection avec des vecteurs d'expression de chaînes lourdes et légères, ainsi qu'un procédé de préparation de ceux-ci. Un anticorps humanisé de la présente invention l'est davantage qu'avec des procédés existants. Il réduit ainsi la probabilité de réponse immunitaire chez l'humain et possède une bonne capacité de liaison à l'antigène, le faisant un excellent candidat pour la prévention et le traitement de l'infection par le virus de l'hépatite B.
PCT/KR2001/001657 2000-10-02 2001-10-04 Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier WO2002059318A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01974926A EP1322761A4 (fr) 2000-10-02 2001-10-04 Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier
JP2002559803A JP2004517636A (ja) 2000-10-02 2001-10-04 Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
US10/148,844 US20030096403A1 (en) 2000-10-02 2001-10-04 Humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR2000/57891 2000-10-02
KR20000057891 2000-10-02
KR10-2001-0060966A KR100484054B1 (ko) 2000-10-02 2001-09-29 Ｂ형 간염 바이러스의 표면항원 ｓ에 대한 인간화 항체 및그의 제조방법
KR2001/60966 2001-09-29

Publications (1)

Publication Number Publication Date
WO2002059318A1 true WO2002059318A1 (fr) 2002-08-01

Family

ID=26638435

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2001/001657 WO2002059318A1 (fr) 2000-10-02 2001-10-04 Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier

Country Status (4)

Country Link
EP (1) EP1322761A4 (fr)
JP (1) JP2004517636A (fr)
CN (1) CN1395617A (fr)
WO (1) WO2002059318A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501312A (ja) * 2004-04-14 2008-01-24 ユーハン・コーポレイション Ｂ型肝炎ウイルスのｓ−表面抗原に対するするヒト化抗体
WO2015153997A3 (fr) * 2014-04-04 2015-11-26 Oncomed Pharmaceuticals, Inc. Anticorps anti-notch 3 et leurs utilisations
US9499613B2 (en) 2008-07-08 2016-11-22 Oncomed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US9617340B2 (en) 2007-01-24 2017-04-11 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9676865B2 (en) 2006-06-13 2017-06-13 Oncomed Pharmaceuticals, Inc. Antibodies to a non-ligand binding region of at least two NOTCH receptors
US10689434B2 (en) 2015-10-09 2020-06-23 Xiamen University Antibody against hepatitis B surface antigen and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1324049C (zh) * 2003-08-04 2007-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗sars冠状病毒基因工程抗体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960002358B1 (ko) * 1993-05-26 1996-02-16 대우통신주식회사 전전자 교환기에서의 시스템 과부하에 의한 교환기 연계 제어방법
US6054297A (en) * 1991-06-14 2000-04-25 Genentech, Inc. Humanized antibodies and methods for making them
KR20000055980A (ko) * 1999-02-12 2000-09-15 박호군 Ｂ형 간염 바이러스의 표면항원 프리-ｓ2에 대한 인간화 항체 및그의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202796D0 (en) * 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
KR100345463B1 (ko) * 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054297A (en) * 1991-06-14 2000-04-25 Genentech, Inc. Humanized antibodies and methods for making them
KR960002358B1 (ko) * 1993-05-26 1996-02-16 대우통신주식회사 전전자 교환기에서의 시스템 과부하에 의한 교환기 연계 제어방법
KR20000055980A (ko) * 1999-02-12 2000-09-15 박호군 Ｂ형 간염 바이러스의 표면항원 프리-ｓ2에 대한 인간화 항체 및그의 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PARK S.S. ET AL: "Generation and characterization of a humanized antibody with specificity for preS2 surface antigen of hepatitis B virus", HYBRIDOMA, vol. 15, no. 6, December 1996 (1996-12-01), pages 435 - 441, XP002980788 *
See also references of EP1322761A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501312A (ja) * 2004-04-14 2008-01-24 ユーハン・コーポレイション Ｂ型肝炎ウイルスのｓ−表面抗原に対するするヒト化抗体
US9676865B2 (en) 2006-06-13 2017-06-13 Oncomed Pharmaceuticals, Inc. Antibodies to a non-ligand binding region of at least two NOTCH receptors
US9617340B2 (en) 2007-01-24 2017-04-11 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9499613B2 (en) 2008-07-08 2016-11-22 Oncomed Pharmaceuticals, Inc. Notch1 receptor binding agents and methods of use thereof
US9505832B2 (en) 2008-07-08 2016-11-29 Oncomed Pharmaceuticals, Inc. Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
WO2015153997A3 (fr) * 2014-04-04 2015-11-26 Oncomed Pharmaceuticals, Inc. Anticorps anti-notch 3 et leurs utilisations
US10689434B2 (en) 2015-10-09 2020-06-23 Xiamen University Antibody against hepatitis B surface antigen and use thereof

Also Published As

Publication number Publication date
JP2004517636A (ja) 2004-06-17
CN1395617A (zh) 2003-02-05
EP1322761A1 (fr) 2003-07-02
EP1322761A4 (fr) 2005-03-23

Similar Documents

Publication Publication Date Title
KR100708398B1 (ko) 인간화 항체 및 이의 제조방법
Hong et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees
WO2016188386A1 (fr) Anticorps vhb anti-pre-s1
Wi et al. Construction and characterization of an anti-hepatitis B virus preS1 humanized antibody that binds to the essential receptor binding site
KR20220131935A (ko) 항angptl3 항체 및 이의 용도
JP3552103B2 (ja) Ｂ型肝炎ウイルスの表面抗原ｐｒｅ−Ｓ１に対するヒト化抗体及びその製造方法
WO2002059318A1 (fr) Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier
CN113817052A (zh) 抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途
CN100516222C (zh) 一种针对hbv s-表面抗原的单克隆抗体可变区及编码它的基因
US20110097270A1 (en) Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus
Kim et al. Enhanced humanization and affinity maturation of neutralizing anti-hepatitis B virus preS1 antibody based on antigen–antibody complex structure
US20030096403A1 (en) Humanized antibody to surface antigen s of hepatitis b virus and a preparing method thereof
CN116589577A (zh) 一种抗人细胞介素5的抗体的制备方法及应用
Ryu et al. A humanized antibody with specificity for hepatitis B surface antigen
JP2004517636A5 (fr)
KR100308758B1 (ko) Ｂ형 간염 바이러스의 표면항원 프리-ｓ2에 대한 인간화 항체 및그의 제조방법
KR100484054B1 (ko) Ｂ형 간염 바이러스의 표면항원 ｓ에 대한 인간화 항체 및그의 제조방법
CN113150131B (zh) 广谱识别a组肠道病毒2c蛋白的单克隆抗体及其应用
KR100345469B1 (ko) B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
KR100246128B1 (ko) 비형 간염 바이러스의 표면항원 프리-에스1에 대한 생쥐 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 그의 제조방법
TW202222836A (zh) 特異性結合糖基化ceacam5的抗體
CA3192254A1 (fr) Anticorps specifiquement lie a ceacam5 glycosyle
CN110759995A (zh) 一种识别HBsAg变异株的人鼠嵌合全分子IgG抗体及其应用
JP2011160696A (ja) 修飾ヒトｉｇｆ−１／ｅペプチドに対する抗体
KR20040058606A (ko) 비형간염바이러스의 에스-표면항원을 인식하는 인간화항체 및 이의 제조방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00494/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018029906

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2002 559803

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10148844

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001974926

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00493/DE

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2001974926

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001974926

Country of ref document: EP